Viridian Therapeutics Inc Stock Price, News & Analysis

Viridian Therapeutics (NASDAQ: VRDN) reported significant progress in its Phase 1/2 trial of VRDN-001 for thyroid eye disease (TED), showing rapid clinical improvement after two infusions. The company has initiated the global Phase 3 THRIVE clinical program. As of September 30, 2022, cash and equivalents totaled $431 million, extending its financial runway into the second half of 2025. The third-quarter net loss increased to $28.9 million, up from $14.0 million year-over-year, primarily due to rising R&D and administrative expenses.

Viridian Therapeutics announced positive topline data from its Phase 1/2 trial of VRDN-001, an anti-IGF-1R antibody for thyroid eye disease (TED). Key findings include:

• 75% proptosis response rate
• 75% overall response rate
• Safety profile remains favorable at 20 mg/kg dose

The study supports the transition to a global Phase 3 THRIVE program, with proof-of-concept data for VRDN-002 expected in 2H23. The company is well-capitalized with $431M, securing operations into 2H25.

Viridian Therapeutics (NASDAQ: VRDN) will participate in the Guggenheim 4^th Annual Neuro/Immunology Conference on November 15, 2022. The company will host a fireside chat at 1:35 p.m. ET. Investors can access the live webcast and subsequent replay through the company's Investors section. Viridian is focused on developing treatments for serious diseases, including thyroid eye disease.

Viridian Therapeutics, Inc. (NASDAQ: VRDN) will announce its financial results for Q3 2022 on November 14, 2022, before market opening. A conference call is scheduled for the same day at 8:00 a.m. ET, accessible via phone or live webcast. The company focuses on developing treatments for serious diseases, with its leading program, VRDN-001, targeting insulin-like growth factor-1 receptor for thyroid eye disease (TED). VRDN-002 and VRDN-003 are enhanced versions of this therapy, aimed at improving patient convenience.

Viridian Therapeutics presented promising data for VRDN-001, an anti-IGF-1R antibody, during three late-breaking presentations at the American Thyroid Association (ATA) 91st Annual Meeting. The Phase 1/2 trial showed an 83% proptosis response and significant reductions in clinical activity scores among patients with active thyroid eye disease (TED) after receiving two 10 mg/kg infusions. The pivotal program for VRDN-001 is scheduled to start this quarter, with additional data from the 20 mg/kg cohort expected soon.

Viridian Therapeutics (VRDN) announced three key presentations at the upcoming Annual Meeting of the American Thyroid Association (ATA) from October 19-23, 2022, in Montreal. These include late-breaking data for VRDN-001 from its Phase 1/2 trial in Thyroid Eye Disease, highlighting its potential as a best-in-class IGF-1R antagonist. The presentations aim to detail the efficacy and differentiation of VRDN-001 compared to existing therapies. Investors can expect further updates on clinical trial results and pharmacokinetics later this quarter.

Viridian Therapeutics (Nasdaq: VRDN) announced the approval of stock options to purchase 103,000 shares of common stock for three new employees as part of Inducement Grants on September 1, 2022. These grants, made outside the company's Amended and Restated 2016 Equity Incentive Plan, aim to incentivize new hires in line with Nasdaq Listing Rule 5635(c)(4). The exercise price equals the closing stock price on the grant date, with a four-year vesting period, beginning with 25% vesting on the first anniversary of employment.

Viridian Therapeutics (NASDAQ: VRDN) announced the issuance of 1,725,000 additional shares at $23.50 each, raising approximately $40.5 million. This follows the previous public offering of 11,352,640 shares, totaling around $311 million in gross proceeds. The funds will support clinical development programs, working capital, and general purposes. The offering was facilitated by Jefferies, SVB Securities, and Evercore ISI. Viridian is focused on developing treatments for underserved diseases, with key programs aimed at thyroid eye disease.

Viridian Therapeutics, Inc. (NASDAQ: VRDN) announced an upsized underwritten public offering, aiming to raise approximately $270 million. The company will sell 9,627,640 shares of common stock at $23.50 each and 28,084 shares of series B preferred stock at $1,566.745, convertible into roughly 1,872,360 shares of common stock. The funds will support clinical development and general corporate purposes. The offering is expected to close on or about August 19, 2022.